Zeeshan Shaikh, MD
Family Medicine · Houston, TXNPI 1114210416
Payments from drug & device makers
Across 243 payments — averaging $3091.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Ironwood Pharmaceuticals, Inc$424K
- Novo Nordisk AS$186K
- Kowa Research Institute, Inc.$113K
- Teva Pharmaceuticals USA, Inc.$26K
- Gilead$2K
- Amgen$57
- plus $117 from 3 others
Across 22 payments — averaging $144.64 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Gilead$2K
- Novo Nordisk AS$1K
What the payments were for
- Travel & lodging$9,73794%
- Food & beverage$6086%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Ironwood Pharmaceuticals, Inc | 33 | $424,470 |
| Novo Nordisk AS | 168 | $186,091 |
| Kowa Research Institute, Inc. | 14 | $112,583 |
| Teva Pharmaceuticals USA, Inc. | 18 | $25,514 |
| Gilead | 2 | $2,312 |
| Amgen | 2 | $57 |
| Genentech USA, Inc. | 3 | $51 |
| Exact Sciences | 2 | $47 |
| Lilly USA, LLC | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Ozempic$8,242
How this compares
$751,143 in reported general payments places this provider in the 95th percentile of 8,760 family medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Rosuvastatin Calcium | 15 | $331 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 12 | $273 |
| Omeprazole | 24 | $228 |
| Metoprolol Succinate | 19 | $218 |
| Atorvastatin Calcium | 29 | $172 |
| Lisinopril | 24 | $117 |
| Metformin Hcl | 33 | $103 |
| Tamsulosin Hcl | 11 | $99 |
| Levothyroxine Sodium | 18 | $95 |
| Azithromycin | 22 | $82 |
| Prednisone | 34 | $60 |
| Lisinopril-HydrochlorothiazideLisinopril/Hydrochlorothiazide | 13 | $53 |
| Naproxen | 19 | $48 |
| Amlodipine Besylate | 21 | $48 |
| Amoxicillin | 14 | $42 |
Paid to pharmacies, not to this prescriber.
Other family medicine in Houston
- Lisa HollowayHouston$30.1M
- Veronica FragosoHouston$24.5M
- Bonnie ColvilleHouston$19.6M
- Oscar de ValleHouston$12.8M
- van TranHouston$11M
- Joe PouzarHouston$10.7M
- Aalia Al-BarwaniHouston$6.8M
- Terence ChangHouston$3.3M
- Douglas DenhamSan Antonio$68.5M
- Vicki MillerPasadena$58.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.